Search results - Portal of Medical Data Models (MDM-Portal)

clinic internal medicine B SHIP-START-3 Vascular stiffness measurement

- 7/3/21 - 1 form, 1 itemgroup, 41 items, 3 languages

Itemgroup: Vascular stiffness measurement

Vascular stiffness measurement form of SHIP Study (Study of Health in Pomerania), conducted by the University Medicine of Greifswald. SHIP unique domain name SHIP.SHIP3.IMB.VAE.VAEOPD. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html. Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617 The English and Portuguese versions of this form are under development.

Other Designated Vascular Report Form SHORT PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

- 3/25/17 - 1 form, 6 itemgroups, 24 items, 1 language

Itemgroups: Study Medication, Pulmonary embolism, Deep vein thrombosis, Retinal Vascular Events, Peripheral arterial occlusion, Ischemic attack

The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one. Complete this page and fax the Event Monitor Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00153062?term=NCT00153062&rank=1

Vascular Diseases

Other Designated Vascular Report Form PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes NCT00153062

- 3/23/17 - 1 form, 9 itemgroups, 29 items, 1 language

Itemgroups: Study Medication, Pulmonary embolism, Deep vein thrombosis, Retinal Vascular Events, Peripheral arterial occlusion, Ischemic attack, Hospitalization, Fatal Outcome, Invenstigator´s Declaration

The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one. Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00153062?term=NCT00153062&rank=1

Rare Vascular Diseases VASCUNET (ESVS) - F.2

- 8/9/23 - 7 forms, 6 itemgroups, 26 items, 1 language

Itemgroups: IG.2, IG.3, IG.4, IG.5, IG.6, IG.7

Draft by PD Dr. Philipp Erhart Klinik für Gefäßchirurgie und Endovaskuläre Chirurgie Heidelberg, Germany

F.3

5 itemgroups 33 items

F.4

1 itemgroup 8 items

F.5

1 itemgroup 9 items

F.1

1 itemgroup 9 items

F.6

1 itemgroup 8 items

F.7

1 itemgroup 12 items

Eligibility Vascular Disease NCT00782015

- 12/2/18 - 1 form, 2 itemgroups, 22 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

Effects of Almonds on Vascular Reactivity in Patients With Coronary Artery Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00782015

Eligibility Endothelial Dysfunction NCT00589888

- 4/30/17 - 1 form, 2 itemgroups, 11 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

FFA-Induced Hypertension and Endothelial Dysfunction; ODM derived from: https://clinicaltrials.gov/show/NCT00589888

dbGaP phs000495 The Gene Partnership (TGP) - eMERGE Data - Eligibility

- 12/13/22 - 5 forms, 1 itemgroup, 7 items, 1 language

Itemgroup: IG.elig

Principal Investigator: Isaac S. Kohane, MD, PhD, Boston Children's Hospital, Boston, MA, USA MeSH: Autistic Disorder,Heart Defects, Congenital,Asthma,Attention Deficit Disorders,Diabetes Mellitus, Type 1,Diabetes Mellitus, Type 2,Epilepsy,Gastrointestinal Diseases,Hypersensitivity,Autoimmune Diseases,Hematologic Diseases,Neoplasms,Arrhythmias, Cardiac,Chromosome Aberrations,Congenital Abnormalities,Dermatology,Developmental Disabilities,Endocrine System,Otolaryngology,Syndrome,Urogenital System,Hearing Loss,Immune System Diseases,Musculoskeletal Abnormalities,Nervous System Diseases,Neuromuscular Diseases,Metabolic Diseases,Nutrition Disorders,Vision Disorders,Mouth Diseases,Mental Disorders,Kidney Diseases,Respiration Disorders,Thyroid Diseases,Vascular Diseases https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000495 The Gene Partnership (TGP) is a prospective longitudinal registry at Boston Children's Hospital (BCH) to study the genetic and environmental contributions to childhood health and disease, collect genetic information on a large number of children who have been phenotyped, and implement the Informed Cohort and the Informed Cohort Oversight Board (ICOB). The term "*The Gene Partnership*" reflects a partnership between researchers and participants. Children seen at BCH are offered enrollment, as are their parents and siblings. DNA is collected on all enrollees. BCH has a comprehensive EMR system, and virtually all inpatient and outpatient data are captured electronically. Clinical data in the BCH EMR is loaded in the i2b2 data warehouse which is available to investigators. Cases, phenotypes, and covariates are ascertained using the i2b2 database. Participants at BCH in TGP have consented to receive any research result and/or incidental finding that arises from studies using TGP that is approved by the Informed Cohort Oversight Board (ICOB) and is in accordance with the participants' preferences; results are returned through the Personally Controlled Health Record (PCHR). BCH and Cincinnati Children's Hospital Medical Center (CCHMC) have partnered as the *P*ediatric *A*lliance for *G*enomic and *E*lectronic Medical Record (EMR) *R*esearch (*PAGER*) site for the eMERGE Phase II network for pediatric institutions, and the cohort for eMERGE at BCH is TGP.

pht002864.v1.p1

1 itemgroup 4 items

pht002865.v1.p1

1 itemgroup 5 items

pht002866.v1.p1

1 itemgroup 42 items

pht002867.v1.p1

1 itemgroup 4 items

Collaborative Research Center | Transregio 240 (Sonderforschungsbereich Transregio 240) - Interview Demography (Interview Demographie)

- 9/17/21 - 1 form, 5 itemgroups, 13 items, 1 language

Itemgroups: Administrative Data, Demography: Living situation, Demography: Marital Status, Demography: Migration background, Demography: Education level

A central patient cohort within the interdisciplinary Collaborative Research Center / Transregio 240 aims to examine the role and function of platelets in different vascular diseases. Demographic and socioeconomic factors are collected within a personal interview with the study participant.

Collaborative Research Center | Transregio 240 (Sonderforschungsbereich Transregio 240) - Follow-Up all centres

- 9/17/21 - 1 form, 6 itemgroups, 25 items, 1 language

Itemgroups: Patient-ID, Follow-Up, Demography: Living situation, Clinical endpoints, WHO (Five) Well-Being Index, Level 2 - Stroke

A central patient cohort within the interdisciplinary Collaborative Research Center / Transregio 240 aims to examine the role and function of platelets in different vascular diseases. This form contains the WHO-5-well being index: WORLD HEALTH ORGANIZATION, REGIONAL OFFICE FOR EUROPE, 1998. Use of well-being measures in primary health care - the DepCare project health for all. Target 12. E60246. Geneva: WHO. This form contains the modified Rankin Scale: Rankin J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis Scottish Med J. 1957; 2: 200–215. This form contains the Barthel-Index: Mahoney F. Barthel D. Functional evaluation: the Barthel Index. Md Med J.1965; 14:61–65. This form contains the Fourth Universal Definition of Myocardial Infarction: Thygesen K et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019; 40(3):237-69.

Collaborative Research Center | Transregio 240 (Sonderforschungsbereich Transregio 240) - Health record (Patientenakte)

- 10/1/20 - 1 form, 8 itemgroups, 41 items, 2 languages

Itemgroups: Patient identification, Study enrolment, Demography, Diagnostic: Echocardiography, Diagnostic: Electrocardiogram, Diagnostic: Blood pressure at admission to hospital, Diagnostic: Risk for cerebral complications, Clinical end points til discharge from hospital

A central patient cohort within the interdisciplinary Collaborative Research Center / Transregio 240 aims to examine the role and function of platelets in different vascular diseases. Information on hospital stay, procedures, medication, complications and in-hospital endpoints are acquired from patient’s hospital records. This form contains the CHA2DS2-Vasc-Score: Lip GYH et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137(2):263–72. This form contains the HAS-BLED score: Pisters R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5):1093–100. This form contains the Fourth Universal Definition of Myocardial Infarction: Thygesen K et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019; 40(3):237-69.

Collaborative Research Center | Transregio 240 (Sonderforschungsbereich Transregio 240) - Arrhythmia

- 10/1/20 - 1 form, 3 itemgroups, 8 items, 1 language

Itemgroups: Patient-ID, Diagnostic analysis: cardiac symptoms, Course of treatment

A central patient cohort within the interdisciplinary Collaborative Research Center / Transregio 240 aims to examine the role and function of platelets in different vascular diseases. In this questionnaire specific items on arrhythmia patients are collected.

Collaborative Research Center | Transregio 240 (Sonderforschungsbereich Transregio 240) - Medication (Medikation)

- 10/1/20 - 1 form, 3 itemgroups, 11 items, 1 language

Itemgroups: Patient identification, Timing of medication, Treatment: Medication

A central patient cohort within the interdisciplinary Collaborative Research Center / Transregio 240 aims to examine the role and function of platelets in different vascular diseases. Information on hospital stay, procedures, medication, complications and in-hospital endpoints are acquired from patient’s hospital records. Note for usage: The item group "Medikation" needs to be filled in as many times as required from the used system. Hinweis zur Anwendung: Die Itemgroup "Medikation" kann bei Verwendung beliebig oft vervielfältigt werden je nach Bedarf.

Keywords

Table of contents

Selected data models